

Hepatocellular Carcinoma/Biliary Tract Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member ID: _____

Treatment Start Date: _____

Stage: _____

Pathology: _____

ECOG Status: 1 2 3 4

ICD-10 Code: _____

Biomarkers/Attributes: (select all that apply)

Biliary Tract Cancers Cholangiocarcinoma

FGFR2:	<input type="checkbox"/>	Fusion or rearrangement	<input type="checkbox"/>	Absent	<input type="checkbox"/>	Not Reported
IDH1:	<input type="checkbox"/>	Mutation	<input type="checkbox"/>	Absent	<input type="checkbox"/>	Not Reported
Microsatellite instability:	<input type="checkbox"/>	dMMR/MSI-H	<input type="checkbox"/>	MSI-L	<input type="checkbox"/>	Not Reported
NTRK Fusion:	<input type="checkbox"/>	Negative	<input type="checkbox"/>	Positive	<input type="checkbox"/>	Not reported

Hepatocellular Carcinoma:

Unresectable, not a transplant candidate, metastatic disease, inoperable by PS or comorbidity | First Line

- Sorafenib
- Lenvatinib
- Atezolizumab + bevacizumab*

Unresectable, not a transplant candidate, metastatic disease, inoperable by PS or comorbidity | Second + Subsequent Lines of Therapy

- Regorafenib
- Cabozantinib
- Sorafenib
- Lenvatinib
- Atezolizumab + bevacizumab*

Biliary Tract Cancers (Gallbladders, intrahepatic and extrahepatic cholangiocarcinoma):

Adjuvant Therapy

- Capecitabine

Unresectable/Metastatic | First Line of Therapy

- Gemcitabine + Cisplatin

Unresectable/Metastatic | Second and Subsequent Lines of Therapy

- Fluorouracil/Leucovorin + Oxaliplatin (FOLFOX)
- Ivosidenib (in IDH1 mutation cholangiocarcinoma)

*a biosimilar agent may be preferred under the patient's specific health plan

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

References:

- Abou-Alfa, G.K., Macarulla, T., Javle, M.M., et al. Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. *Lancet Oncol.* 2020;21(6):796-807. doi:10.1016/S1470-2045(20)30157-1
- Abou-Alfa, G.K., Meyer, T., Cheng, A.L., et al. (2018, July 5). Cabozantinib in Patients With Advanced and Progressing Hepatocellular Carcinoma. Retrieved from [ncbi.nlm.nih.gov/pubmed/?term=29972759](https://pubmed.ncbi.nlm.nih.gov/?term=29972759)
- Abou-Alfa, G.K., Sahai, V., Hollebecque, A., et al. Pemigatinib for Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma: A Multicentre, Open-Label, Phase 2 Study. *Lancet Oncol.* 2020;21(5):671-684. doi:10.1016/S1470-2045(20)30109-1
- André, T., Reyes-Vidal, J.M., Fartoux, L., et al. (2008, Sept. 16). Gemcitabine and Oxaliplatin in Advanced Biliary Tract Carcinoma: A Phase II Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/19238628](https://pubmed.ncbi.nlm.nih.gov/19238628)
- Ben-Josef, E., Guthrie, K.A., El-Khoueiry, A.B., et al. (2015, Aug. 20). SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Retrieved from [ncbi.nlm.nih.gov/pubmed/25964250](https://pubmed.ncbi.nlm.nih.gov/25964250)
- Bruix, J., Qin, S., Merle, P., et al. (2017, Jan. 7). Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/27932229](https://pubmed.ncbi.nlm.nih.gov/27932229)
- Caparica, R., Lengelé, A., Bekolo, W., et al. FOLFIRI as Second-Line Treatment of Metastatic Biliary Tract Cancer Patients. *Autops Case Rep.* 2019 Jun 24;9(2):e2019087. doi: 10.4322/acr.2019.087. PMID: 31528622; PMCID: PMC6738847
- Cheng, A.-L., Kang, Y.-K., Chen, Z., et al. (January 2009). Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region With Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/19095497](https://pubmed.ncbi.nlm.nih.gov/19095497)
- Ducreux, M., Van Cutsem, E., Van Laethem, J.L., et al. (February 2005). A Randomised Phase II Trial of Weekly High-Dose 5-Fluorouracil With and Without Folinic Acid and Cisplatin in Patients With Advanced Biliary Tract Carcinoma: Results of the 40955 EORTC Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/15691639](https://pubmed.ncbi.nlm.nih.gov/15691639)
- Ducreux, M., Van Cutsem, E., Van Laethem, J.L., et al. (February 2005). A Randomised Phase II Trial of Weekly High-Dose 5-Fluorouracil With and Without Folinic Acid and Cisplatin in Patients With Advanced Biliary Tract Carcinoma: Results of the 40955 EORTC Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/15691639](https://pubmed.ncbi.nlm.nih.gov/15691639)
- Ebata, T., Hirano, S., Konishi, M., et al. (February 2018). Randomized Clinical Trial of Adjuvant Gemcitabine Chemotherapy Versus Observation in Resected Bile Duct Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/29405274](https://pubmed.ncbi.nlm.nih.gov/29405274)
- Eckel, F., Schmid, R.M. (2007, March 26). Chemotherapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials. Retrieved from [ncbi.nlm.nih.gov/pubmed/17325704](https://pubmed.ncbi.nlm.nih.gov/17325704)
- Edeline, J., Bonnetain, F., Phelip, J.M., et al. (2017, Feb. 1). Gemox Versus Surveillance Following Surgery of Localized Biliary Tract Cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) Phase III Trial. Retrieved from ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.225

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017, June 24). Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/28434648](https://pubmed.ncbi.nlm.nih.gov/28434648)

Finn, R.S., Qin, S., Ikeda, M., et al. Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med.* 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160

Finn, R.S., Qin, S., Ikeda, M., et al. IMbrave150: Updated Overall Survival (OS) Data From a Global, Randomized, Open-Label Phase III Study of Atezolizumab (atezo) + Bevacizumab (bev) vs. Sorafenib (sor) in Patients (pts) With Unresectable Hepatocellular Carcinoma (HCC). *J Clin Oncol.* 2021;39(suppl 3):267. Retrieved from bit.ly/2LVd9Mu

Finn, R.S., Ryoo, B.-Y., Merle, P., et al. (2019, Dec. 2). Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/31790344](https://pubmed.ncbi.nlm.nih.gov/31790344)

Ghidini, M., Pizzo, C., Botticelli, A., et al. (2018, Dec. 28). [Full text] Biliary Tract Cancer: Current Challenges and Future Prospects: CMAR. Retrieved from dovepress.com/biliary-tract-cancer-currentchallenges-and-future-prospects-peer-reviewed-fulltext-article-CMAR

Graham, J.S., Boyd, K., Coxon, F.Y., et al. (2016, March 12). A Phase II Study of Capecitabine and Oxaliplatin Combination Chemotherapy in Patients With Inoperable Adenocarcinoma of the Gall Bladder or Biliary Tract. Retrieved from [ncbi.nlm.nih.gov/pmc/articles/PMC4788848](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC4788848)

Iqbal, S., Rankin, C., Lenz, H.J., et al. (December 2011). A Phase II Trial of Gemcitabine and Capecitabine in Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma: Southwest Oncology Group Study S0202. Retrieved from [ncbi.nlm.nih.gov/pubmed/21556747](https://pubmed.ncbi.nlm.nih.gov/21556747)

Kim, T.W., Chang, H.M., Kang, H.J., et al. (July 2003). Phase II Study of Capecitabine Plus Cisplatin as First-Line Chemotherapy in Advanced Biliary Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/12853355](https://pubmed.ncbi.nlm.nih.gov/12853355)

Knox, J.J., Hedley, D., Oza, A., et al. (2005, April 1). Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/15800324](https://pubmed.ncbi.nlm.nih.gov/15800324)

Kudo, M., Finn, R.S., Qin, S., et al. (2018, March 24). Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/?term=29433850](https://pubmed.ncbi.nlm.nih.gov/?term=29433850)

Lamarca, A., Hubner, R.A., David Ryder, W., et al. (December 2014). Second-Line Chemotherapy in Advanced Biliary Cancer: A Systematic Review. Retrieved from [ncbi.nlm.nih.gov/pubmed/24769639](https://pubmed.ncbi.nlm.nih.gov/24769639)

Lee, J., Park, S.H., Chang, H.-M., et al. (February 2012). Gemcitabine and Oxaliplatin With or Without Erlotinib in Advanced Biliary-Tract Cancer: A Multicentre, Open-Label, Randomised, Phase 3 Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/22192731](https://pubmed.ncbi.nlm.nih.gov/22192731)

Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2008, July 24). Sorafenib in Advanced Hepatocellular Carcinoma. Retrieved from [ncbi.nlm.nih.gov/pubmed/18650514](https://pubmed.ncbi.nlm.nih.gov/18650514)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Moehler, M., Maderer, A., Schimanski, C., et al. (December 2014). Gemcitabine Plus Sorafenib Versus Gemcitabine Alone in Advanced Biliary Tract Cancer: A Double-Blind Placebo-Controlled Multicentre Phase II AIO Study With Biomarker and Serum Programme. Retrieved from [ncbi.nlm.nih.gov/pubmed/25446376](https://pubmed.ncbi.nlm.nih.gov/25446376)

National Cancer Institute. Cancer Statistics. Retrieved from seer.cancer.gov/statfacts/html/livibd.html

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Accessed Jan 20, 2020

Nehls, O., Klump, B., Arkenau, H.T., et al. (2002, Sept. 23). Oxaliplatin, Fluorouracil and Leucovorin for Advanced Biliary System Adenocarcinomas: A Prospective Phase II Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/12232749](https://pubmed.ncbi.nlm.nih.gov/12232749)

Nehls, O., Oettle, H., Hartmann, J.T., et al. (2008, Jan. 29). Capecitabine Plus Oxaliplatin as First-Line Treatment in Patients With Advanced Biliary System Adenocarcinoma: A Prospective Multicentre Phase II Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/18182984](https://pubmed.ncbi.nlm.nih.gov/18182984)

Okusaka, T., Nakachi, K., Fukutomi, A., et al. (2010, Aug. 10). Gemcitabine Alone or in Combination With Cisplatin in Patients With Biliary Tract Cancer: A Comparative Multicentre Study in Japan. Retrieved from [ncbi.nlm.nih.gov/pubmed/20628385](https://pubmed.ncbi.nlm.nih.gov/20628385)

Primrose, J.N., Fox, R.P., Palmer, D.H., et al. (May 2019). Capecitabine Compared With Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/30922733](https://pubmed.ncbi.nlm.nih.gov/30922733)

Qin, S., Bai, Y., Lim, H.Y., et al. (2013, Oct. 1). Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin as Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma from Asia. Retrieved from [ncbi.nlm.nih.gov/pubmed/23980077](https://pubmed.ncbi.nlm.nih.gov/23980077)

Riechelmann, R.P., Townsley, C.A., Chin, S.N., et al. (2007, Sept. 15). Expanded Phase II Trial of Gemcitabine and Capecitabine for Advanced Biliary Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/17628484](https://pubmed.ncbi.nlm.nih.gov/17628484)

Sangro, B., Melero, I., Wadhawan, S., et al. Association of Inflammatory Biomarkers With Clinical Outcomes in Nivolumab-Treated Patients With Advanced Hepatocellular Carcinoma. *J Hepatol.* 2020 Dec;73(6):1460-1469. doi: 10.1016/j.jhep.2020.07.026. Epub 2020 Jul 22

Sharma, A., Dwary, A.D. & Mohanti, B.K. (2010, Oct. 20). Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/20855823](https://pubmed.ncbi.nlm.nih.gov/20855823)

Shroff, R.T., Kennedy, E.B., Bachini, M., et al. (2019, April 20). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Retrieved from [ncbi.nlm.nih.gov/pubmed/30856044](https://pubmed.ncbi.nlm.nih.gov/30856044)

Shroff, R.T., Kennedy, E.B., Bachini, M., et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. *J Clin Oncol.* 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11. PMID: 30856044

Stein, A., Arnold, D., Bridgewater, J., et al. (2015, July 31). Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gallbladder Carcinoma (ACTICCA-1 Trial) – A Randomized, Multidisciplinary, Multinational phase III Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/26228433](https://pubmed.ncbi.nlm.nih.gov/26228433)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Sun, W., Patel, A., Normolle, D., et al. A Phase 2 Trial of Regorafenib as a Single Agent in Patients With Chemotherapy-Refractory, Advanced and Metastatic Biliary Tract Adenocarcinoma. *Cancer*. 2019 Mar 15;125(6):902-909. doi: 10.1002/cncr.31872. Epub 2018 Dec 18. PMID: 30561756; PMCID: PMC6402964

Valle, J., Wasan, H., Palmer, D.H., et al. (2010, April 8). Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/20375404

Yau, T., Hsu, C., Kim, T.Y., et al. Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib Experienced Asian Cohort Analysis. *J Hepatol*. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7. Erratum in: *J Hepatol*. 2019 Dec;71(6):1278

Yau, T., Kang, Y.K., Kim, T.Y., et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. *JAMA Oncol*. 2020 Oct 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub ahead of print. PMID: 33001135; PMCID: PMC7530824.040

Yau, T., Park, J.W., Finn, R.S., et al. (2019, Sept. 27). CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs. Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC). Retrieved from oncologypro.esmo.org/MeetingResources/ESMO-2019-Congress/CheckMate-459-A-Randomized-Multi-Center-Phase-3-Study-ofNivolumab-NIVO-vs-Sorafenib-SOR-as-First-Line-1L-Treatment-in-Patients-pts-With-AdvancedHepatocellular-Carcinoma-aHCC

Zhu, A.X., Finn, R.S., Edeline, J., et al. (July 2018). Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (KEYNOTE-224): A Non-Randomised, OpenLabel Phase 2 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/29875066 32

Zhu, A.X., Kang, Y.-K., Yen, C.-J., et al. (February 2019). Ramucirumab After Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Increased α -Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/30665869

Zhu, A.X., Rosmorduc, O., Evans, T.R.J., et al. (2015, Feb. 20). SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Retrieved from ncbi.nlm.nih.gov/pubmed/25547503

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.